Q-omics provides the consensus-scored MS4A1 profile across patient tissues and cancer cell-line models. MS4A1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MS4A1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MS4A1 RNA expression shows 18,066 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where MS4A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A1 survival associations across molecular data types. MS4A1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A1 RNA expression–survival associations across cancer types. High MS4A1 expression shows favorable associations in HNSC, LUAD, SKCM, OV, BRCA and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MS4A1 RNA expression.
This table summarizes MS4A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MS4A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A1 shows lower tumor expression in COAD, BLCA, PAAD and THCA and higher tumor expression in LUAD and STAD. The COAD box plot shows higher MS4A1 RNA expression in normal versus tumor tissue (log2 FC = −1.725, t-test p < 0.001).
This table shows molecular features associated with MS4A1 in patient tissues and cancer cell lines. In patient samples, MS4A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and PANCREAS.
